- In February 2024, the Food and Drug Administration (FDA) accepted Galderma's Biological License Application (BLA) for Nemolizumab, a treatment targeting both atopic dermatitis and prurigo nodularis. This acceptance marks a significant step forward in the regulatory process, paving the way for potential approval of this innovative therapy. If approved, Nemolizumab could provide an important new option for patients suffering from these chronic skin conditions
- In June 2023, Novartis announced its agreement to acquire Chinook Therapeutics, a Seattle-based clinical-stage biopharmaceutical company known for developing two promising late-stage therapies for rare and severe chronic kidney diseases. This acquisition, which is contingent upon customary closing conditions, aligns with Novartis's strategic focus on innovative medicines. By integrating Chinook’s portfolio, Novartis aims to significantly enhance its renal offerings and complement its existing pipeline of treatments
- In February 2023, Pfizer announced an ambitious plan to launch an unprecedented 19 new products over the next 18 months. This strategic initiative reflects the company's commitment to innovation and expanding its therapeutic offerings. With a robust pipeline, Pfizer aims to address unmet medical needs and strengthen its position in the pharmaceutical market
- In October 2023, Dermavant Sciences, a clinical-stage biopharmaceutical company, announced encouraging results from their pivotal phase 3 trials for VTAMA Cream (tapinarof), specifically targeting pruritus. This treatment is aimed at children as young as two years old, addressing a condition that affects approximately 1% of adults with atopic dermatitis. The data highlights the cream's effectiveness in alleviating symptoms such as itching, burning, and redness, emphasizing its potential to significantly improve patient quality of life
Frequently Asked Questions
The market is segmented based on Segmentation, By Treatment (Medication, Cryotherapy, Phototherapy, Pulsed Dye Laser, and Others), Diagnosis (Skin Biopsy, Blood Tests, and Others), Dosage (Injection, Tablets, Ointments, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Prurigo Nodularis Treatment Market size was valued at USD 1.22 USD Billion in 2023.
The Global Prurigo Nodularis Treatment Market is projected to grow at a CAGR of 3.86% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
